Condition: Non-Small Cell Lung Cancer · Sponsor: Dizal (Jiangsu) Pharmaceutical Co., Ltd.
To assess the efficacy and safety of sunvozertinib versus placebo as adjuvant therapy in patients with stage IB-IIIA non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins) or P-loop and αC-helix compression (PACC) mutations, who have had radical surgery, regardless of adjuvant chemotherapy.
This description comes directly from the study's public registry record.
Sherry Hu, MD, PhD · +86 2161098345 · sherry.hu@dizalpharma.com
Always discuss trial participation with your own doctor first.
| Beijing Cancer Hospital | Beijing, China | Not Yet Recruiting |
| Beijing Chest Hospital, Capital medical university | Beijing, China | Not Yet Recruiting |
| Cancer Hospital Chinese Academy of Medical Sciences | Beijing, China | Not Yet Recruiting |
| China-Japan Friendship hospital | Beijing, China | Not Yet Recruiting |
| Peking Union Medical College Hospital | Beijing, China | Not Yet Recruiting |
| Xuanwu Hospital Capital Medical University | Beijing, China | Not Yet Recruiting |
| The First Hospital of Jilin University | Changchun, China | Recruiting |
| Hunan Cancer Hospital | Changsha, China | Not Yet Recruiting |
| The Third Xiangya Hospital of Central South University | Changsha, China | Not Yet Recruiting |
| Xiangya Hospital of Central South University | Changsha, China | Not Yet Recruiting |
| Sichuan Cancer Hospital | Chengdu, China | Not Yet Recruiting |
| West China Hospital Sichuan University | Chengdu, China | Not Yet Recruiting |
+ 37 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07182682